[1] 钟锐, 邬麟, 江美林, 等.EGFR-TKIs获得性耐药的机制及其治疗的研究进展[J].肿瘤药学, 2017, 7(6):641. doi: 10.3969/j.issn.2095-1264.2017.06.01
[2] MAEMONDO M, INOUE A, KOBAYASHI K, et al.Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR[J].N Engl J Med, 2010, 362(25):2380. doi: 10.1056/NEJMoa0909530
[3] MOK TS, WU YL, THONGPRASERT S, et al.Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma[J].N Engl J Med, 2009, 361(10):947. doi: 10.1056/NEJMoa0810699
[4] MITSUDOMI T, MORITA S, YATABE Y.Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor(WJTOG3405):an open label, randomised phase 3 trial[J].Lancet Oncol, 2010, 11(2):121. doi: 10.1016/S1470-2045(09)70364-X
[5] COSTA DB, KOBAYASHI SS.Whacking a molecule:clinical activity and mechanisms of resistance to third generation EGFR inhibitors in EGFR mutated lung cancers with EGFR-T790M[J].Transl Lung Cancer Res, 2015, 4(6):809.
[6] KOBAYASHI S, BOGGON TJ, DAYARAM T, et al.EGFR mutation and resistance of non-small-cell lung cancer to gefitinib[J].N Engl J Med, 2005, 352(8):786. doi: 10.1056/NEJMoa044238
[7] NGUYEN KS, KOBAYASHI S, COSTA DB.Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway[J].Clin Lung Cancer, 2009, 10(4):281. doi: 10.3816/CLC.2009.n.039
[8] 倪琛琛, 于敏, 张志红.EGFR与PI3K/AKT信号通路相关蛋白在非小细胞肺癌组织中的表达及其意义[J].安徽医科大学学报, 2011, 46(12):1264. doi: 10.3969/j.issn.1000-1492.2011.12.012
[9] BAEHMAN KE, ARGANI P, SAMUELS Y, et al.The PIK3CA gene is mutated with high frequency in human breast cancers[J].Cancer Biol Ther, 2004, 3(8):772. doi: 10.4161/cbt.3.8.994
[10] DE LAURENTⅡS A, PARDO OE, PALAMIDESSI A, et al.The catalytic class Ⅰ(A) PI3K isoforms play divergent roles in breast cancer cell migration[J].Cell Signal, 2011, 23(3):529. doi: 10.1016/j.cellsig.2010.10.021
[11] BABA Y, NOSHO K, SHIMA K, et al.Phosphorylated AKT expression is associated with PIK3CA mutation, low stage, and favorable outcome in 717 colorectal cancers[J].Cancer, 2011, 117(7):1399. doi: 10.1002/cncr.25630
[12] DE MARCO C, RINALDO N, BRUNI P, et al.Multiple genetic alterations within the PI3K pathway are responsible for AKT activation in patients with ovarian carcinoma[J].PLoS One, 2013, 8(2):e55362. doi: 10.1371/journal.pone.0055362
[13] WEIGELT B, WARNE PH, LAMBROS MB, et al.PI3K pathway dependencies in endometrioid endometrial cancer cell lines[J].Clin Cancer Res, 2013, 19(13):3533. doi: 10.1158/1078-0432.CCR-12-3815
[14] VERENA S, JESSICA LU, JAN D, et al.Identification of uncommon PIK3CA mutations in lung cancer by using pyrosequencing[J].Diagn Mol Pathol, 2013, 22(1):22. doi: 10.1097/PDM.0b013e31825f5f93
[15] MARLENA W, SANGITA M, PRAMOD P, et al.targeting small cell lung cancer harboring mutation with PIK3CA a selective oral PI3K inhibitor PF-4989216[J].Clin Cancer Res, 2014, 20(3):631. doi: 10.1158/1078-0432.CCR-13-1663
[16] ZHAO Q, ZHANG B, SHAO YF, et al.Correlation between the expression levels of miR-1 and PIK3CA in non-small cell lung cancer and their relationship with clinical characteristics and prognosis[J].Future Oncol, 2014, 10(1):49. doi: 10.2217/fon.13.242
[17] WANG L, HU HC, PAN YJ, et al.PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup[J].PLoS One, 2014, 9(2):e88291. doi: 10.1371/journal.pone.0088291
[18] VANDERLAAN PA, RANGACHARI D, MOCKUS SM, et al.Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutatedlung cancers:correlation with clinical outcomes[J].Lung Cancer, 2017, 106(4):17.
[19] COLLISSON EA, CAMPBELL JD.Brooks AN.Cancer genome atlas research network.comprehensive molecular profiling of lung adenocarcinoma[J].Nature, 2014, 511(7):543.
[20] COSTA DB, HALMOS B, KUMAR A, et al.BIM mediates EGFR tyrosine kinaseinhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations[J].PLoS Med, 2007, 4(10):1669.
[21] MCGRANAHAN N, FAVERO F, DE BRUIN EC, et al.Clonal status of actionable driver events and the timing of mutationalprocesses in cancer evolution[J].Sci Transl Med, 2015, 283(7):54.
[22] MACHADO-RUGOLO J, FABRO AT, ASCHERI D, et al.Usefulness of complementary next-generation sequencing and quantitative immunohistochemistry panels for predicting brain metastases and selecting treatment outcomes of non-small cell lung cancer[J].Hum Pathol, 2019, 83(1):177.
[23] SULLIVAN I, PLANCHARD D.Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer:clinical trial evidence and experience[J].Ther Adv Respir Dis, 2016, 10(6):54.
[24] DURUISSEAUX M, BESSE B, CADRANEL J, et al.Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer(IFCT-1302 CLINALK):a French nationwide cohort retrospective study[J].Oncotarget, 2017, 8(13):21903.
[25] HELLMANN MD, NATHANSON T, RIZVI H, et al.Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer[J].Cancer Cell, 2018, 33(5):843. doi: 10.1016/j.ccell.2018.03.018